Lacidipine Loaded Solid Lipid Nanoparticles for Oral Delivery: Preparation, Characterization and In vivo Evaluation
DOI:
https://doi.org/10.37285/ijpsn.2016.9.6.2Abstract
The objective of this study was to develop and evaluate lacidipine (LD) loaded solid lipid nanoparticles (LD-SLNs) for improving the oral bioavailability. LD-SLNs were prepared in two steps. First step was hot homogenization and next by ultrasonication method, using triglycerides (tripalmitin and tristearin), monoglyceride and surfactants (Poloxamer 188 and egg lecithin E80). The prepared LD-SLNs were characterized for particle size, PDI, zeta potential, drug content, entrapment efficiency (EE %). In vitro drug release studies using a dialysis bag method in 0.1N HCl and pH 6.8 phosphate buffer were conducted. In addition, long-term physical stability of the optimized SLNs was investigated at refrigerated and room temperature for 60 days. FTIR and DSC studies revealed that no interaction between the drug and lipids. LD-SLNs prepared with Dynasan-116 (F3), having the size of 141.86nm, PDI of 0.293, ZP of -22.3 m with 94.75% of EE was optimized and was stable for 60days. Scanning electron microscopic studies showed nearly spherical shaped particles. Further, pharmacokinetic studies were conducted in wistar rats. The relative bioavailability of LD in SLNs was 2.03 times when compared with that of the LD suspension. The results are indicative of SLNs as suitable lipid based carrier system for improving the oral bioavailability of LD.
Downloads
Metrics
Keywords:
Lacidipine, Solid lipid nanoparticles, Oral bioavailability, Triglycerides, Poloxomer, Pharmacokinetics
Downloads
Published
How to Cite
Issue
Section
References
Amit M, Shivang C, Niyaz M and Arun KM (2012). Solid-state characterization of lacidipine/PVP K 29/32 solid dispersion primed by solvent co-evaporation. Int J Pharm Inv 2: 90-96.
Andrew JH and William NC (1997). Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deli Rev 25: 103-128.
Anuradha K and Senthil Kumar M (2014). Development of Lacidipine loaded nanostructured lipid carriers (NLCs) for bioavailability enhancement. Int J Pharm Med Res 2: 50-57.
Cavalli R, Caputo O, Carlotti ME, Trotta M, Scarnecchia C and Gasco MR (1997). Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles. Int J Pharm 148: 47-54.
Dahan A and Hoffman A (2008). Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J Control Rel 129: 1-10.
De Filippis P, Bovina E, Da Ros L, Fiori J and Cavrini V (2002). Photodegradation studies on lacidipine in solution: basic experiments with a cis–trans reversible photoequilibrium under UV-A radiation exposure. J Pharm Biomed Ana 27: 803-812.
Frank TM, Antonella R and Matilde M (1992). Lacidipine: a dihydropyridine calcium antagonist with antioxidant activity. Free Rad Bio Med 12: 183-187.
Manjunath K and Venkateswarlu V (2005). Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Rel 107: 215-228.
Mannur V, Mastiholimath V, Kharya R and Patware P (2012). Development and validation of a hplc method for the determination of lacidipine in pure form and in pharmaceutical dosage form. Mala J Ana Sci 16: 213 - 219.
McCormack PL and Wagstaff AJ (2003). Lacidipine: a review of its use in the management of hypertension. Drugs 63: 2327-56.
Mehnert W and Mäder K (2001). Solid lipid nanoparticles production, characterization and applications. Adv Drug Deliv Rev 47: 165-196.
Mehnert W and Mäder K (2012). Solid lipid nanoparticles production, characterization and applications. Adv Drug Deliv Rev 64: 83-101.
Mülhen AZ, Schwarz C and Mehnert W (1998).Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm 45: 149-55.
Müller RH, Mäder K and Gohla S (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery a review of the state of the art. Eur J Pharm Biopharm 50: 161-177.
Narendar D and Kishan V (2015). Pharmacokinetic and pharmacodynamic studies of nisoldipine loaded solid lipid nanoparticles by central composite design. Drug Dev Ind Pharm 41: 1968-77
Narendar D and Kishan V (2016). Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation. Drug Deliv 23: 395-404.
Pellegatti M, Grossi P, Ayrton J, Evans GL and Harker AJ (1990). Absorption, distribution and excretion of lacidipine, a dihydropyridine calcium antagonist, in rat and dog. Xenobiotica 20: 765-77.
Schwarz C, Mehnert W, Lucks JS and Müller RH (1994). Solid lipid nanoparticles (SLN) for controlled drug delivery-I. Production, characterization and sterilization. JControl Rel 30: 83-96.
Shamsunder D, Sandip C, Aruna K and Krutika KS (2013). Solid lipid nanoparticles and nanosuspension of adefovir dipivoxil for bioavailability improvement: formulation, characterization, pharmacokinetic and biodistribution studies. Drug Dev Ind Pharm 39: 733-743.
Suvarna G, Narender D and Kishan V (2015). Preparation, characterization and in vivo evaluation of rosuvastatin calcium loaded solid lipid nanoparticles. Int J Pharm Sci Nanotech 9: 2779-2785.
Thatipamula RP, Palem CR, Gannu R, Mudragada S and Yamsani MR (2011). Formulation and in vitro characterization of domperidone loaded solid lipid nanoparticles and nanostructured lipid carriers. Daru 19: 23-32.
Venkateswarlu V and Manjunath K (2004). Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Rel 95: 627- 638.
Vinay Kumar V, Raghavendra C, Rojarani K, Laxminarayana A, Ramakrishna S and Prakash VD (2012).Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: A novel strategy to avoid intraduodenal administration. Colloids Surf B 95: 1-9.
Weijia Z, Jain A, Papoutsakis D, Rose-Marie, Dannen-felser, Riccardo P and Sudhakar G (2012). Selection of oral bioavailability enhancing formulations during drug discovery. Drug Dev Ind Pharm 38: 235-247.
